QuantumDx

The firm also announced the appointment of new board members as it heads toward commercialization of a portable MDx platform.

The test will be developed in Global Good labs and ported onto QuantuMDx's handheld molecular platform.

Q-POC

The funding will be used to further develop a 20-minute tuberculosis detection assay and drug susceptibility test using the firm's handheld Q-POC microfluidic PCR system.

QuantuMDx says its low-cost, handheld device will be able to quickly diagnose patients, as the Guardian reports.

QuantuMDx will use Scienion's ultra-low-volume liquid handling technologies in its Q-Poc handheld molecular diagnostic device.

The California Institute of Technology has been awarded

NEW YORK (GenomeWeb) – The Foundation for Innovative New Diagnostics is collaborating with multiple firms to accelerate the development of low-cost molecular diagnostics for tuberculosis and drug resistance determination, the non-profit organization said today.

NEW YORK (GenomeWeb) – QuantuMDx, a Newcastle, UK-based molecular diagnostics company, last week announced that it had successfully completed the development of its Q-POC handheld testing device.

John Burn has been appointed as a non-executive director of NHS England, QuantuMDx said this week.

NEW YORK (GenomeWeb) — QuantuMDx will use the proceeds from a recent financing round to optimize its handheld Q-POC molecular diagnostic device as well as several assays ahead of planned launches in 2015 and 2016.

Pages

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.